Figure 2 | Leukemia

Figure 2

From: Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin

Figure 2

Points of action of the pretreatment effect of DAC. (a) Change in the expression of CD33 antigen was measured with a flow cytometer. CD33 antigen expression (MFI) was decreased after 4-h incubation with anti-CD33 antibody (shaded curves). Dotted curves represent isotype controls. (b, c) Activity and mRNA expression of MRP1 with or without DAC treatment. MRP1 activity was reduced by DAC treatment in K052 cells, whereas no change was seen in SKM-1 or Kasumi-3 cells (b). mRNA expression of MRP1 was reduced by DAC treatment in K052 cells (c). (d) DNA fragmentation by GO was enhanced by DAC pretreatment in K052 and SKM-1 cells. DAC pretreatment produced no increase in DNA fragmentation by GO in SKK-1 cells.

Back to article page